The company ended fiscal year 2025 with $310.3 million in cash and guided its cash runway until 2028. Analysts highlight potential in Sionna's CF drug candidates, particularly the NBD1 stabilizers SION-719 and SION-451, with proof-of-concept readouts anticipated by mid-2026.
Cyborg Score Rationale
Two analysts have rated the stock with a Strong Buy rating and eight with a Buy rating, with a consensus target price of $47.63. Strong cash position and near-term clinical data catalysts support momentum, though company remains unprofitable.
Top Insights
Key near-term catalysts: NBD1 stabilizers SION-719 and SION-451 proof-of-concept data expected mid-2026.
Substantial cash runway extending to 2028 provides operational flexibility without near-term financing pressure.
Recent analyst coverage expansion includes Lifesci Capital strong-buy, Citizens JMP market outperform with $63 PT, and multiple Buy ratings from major houses.
Company filed $250M ATM shelf for potential future capital raising with Leerink Partners.
Named Competitors
Kalydeco/Orkambi/Trikafta — Established CF modulators; Trikafta market leader for F508del CF
Eluprerafan (VX-659) & other modulators — Academic/consortium-based CF research programs